Applied DNA Sciences Inc. has announced that it received a notice from Nasdaq indicating that the company no longer meets the $1.00 minimum bid price requirement necessary for continued listing on The Nasdaq Capital Market. This deficiency was identified after the company's common stock maintained a bid price below $1.00 per share for 32 consecutive business days from April 14 to May 29, 2025. In response, Applied DNA Sciences implemented a 1-for-15 reverse stock split to regain compliance. However, the company is not eligible for a compliance period due to recent reverse stock splits. As a result, its securities are at risk of being delisted unless a hearing request is granted by the Nasdaq Hearings Panel. The company has requested a hearing to defer any suspension or delisting actions, but there is no assurance that their request will be approved or that compliance will be regained.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。